TLDR High-quality validation studies are needed to improve alopecia areata patient-reported outcome measures.
This systematic review evaluated the quality of alopecia areata-specific patient-reported outcome measures (PROMs) and identified a need for high-quality validation studies on their internal structure. The review analyzed 15 articles, including 8 developmental and 7 validation studies, covering 11 PROMs. Three PROMs focused on health-related quality of life, five were symptom-based, and three combined constructs. The Alopecia Areata Patient Priority Outcomes (AAPPO) was highlighted for its high-quality evidence of structural validity, internal consistency, and test-retest reliability. However, no study reported measurement error. The review emphasizes the importance of rigorous psychometric testing to improve the quality of AA-specific PROMs.
8 citations
,
June 2023 in “British Journal of Dermatology” The SAAD-41 scale effectively measures the psychosocial impact of alopecia areata.
22 citations
,
November 2021 in “Dermatology and Therapy” The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.
11 citations
,
March 2021 in “Dermatology and therapy” Researchers created a new tool to measure the effects of alopecia areata from the patient's view, focusing on hair loss, daily life, and emotional health.
7 citations
,
January 2021 in “Dermatology and therapy” Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.
30 citations
,
September 2020 in “Journal of Patient-Reported Outcomes” Alopecia Areata (AA) causes significant emotional distress, including feelings of embarrassment, depression, and anxiety, and impacts social interactions and daily activities.
56 citations
,
August 2020 in “American Journal of Clinical Dermatology” New tools help assess eyebrow, eyelash, and nail changes in Alopecia Areata, improving understanding of patient experiences.